July 26th 2024
The CAR T-cell therapy UCART22 has been granted orphan drug designation and rare pediatric drug designation from the FDA for the treatment of acute lymphoblastic leukemia.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
NDA Submitted to the FDA for Imetelstat in R/R Myelodysplastic Syndrome
June 21st 2023Following positive data from the phase 3 IMerge study of imetelstat, the FDA has received a new drug submission for the agent for the treatment of patients with relapsed or refractory myelodysplastic syndrome.
Read More
Roxadustat Misses Efficacy End Point in Phase 3 MDS Study
May 12th 2023The proportion of patients with myelodysplastic syndromes who achieved red blood cell transfusion independence in the first 28 weeks was 47.5% for patients given roxadustat vs 33.3% for patients given placebo for the treatment of anemia.
Read More
Mosunetuzumab Maintains Efficacy/Survival Benefit in Elderly Patients With DLBCL
May 5th 2023In an interview with Targeted Oncology, Adam J. Olszewski, MD, discussed mosunetuzumab and the rationale and findings of this phase 1b/2 study assessing the agent in elderly patients with diffuse large B-cell lymphoma.
Read More
FDA Accepts sBLA of Luspatercept for Anemia in Patients With Lower-Risk MDS
May 1st 2023Findings from the COMMANDS study in which luspatercept showed statistically significant and clinically meaningful improvements for patients with low-risk myelodysplastic syndrome, the FDA has set a target action date of August 28, 2023.
Read More
FDA Halts Phase 1 Study MT-0169 Due to Unacceptable Toxicity
April 12th 2023Multiple cases of unacceptable toxicity requiring dose reductions have occurred in a phase 1 study of MT-0169 in patients with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma. The FDA has placed a partial clinical hold on the study
Read More
Roundtable Discussion: Carraway Assesses Remaining Challenges in BPDCN Patient Population
April 8th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Hetty E. Carraway, MD, MBA, discussed with participants diagnosing and treating patients with BPDCN, as well as the remaining challenges in this space.
Read More
Updates on Recent Advances and Treatments for Hematologic Malignancies
March 22nd 2023In an interview with Targeted Oncology, Guenther Koehne, MD, PhD, provided an overview of The Summit of Americas on Immunotherapies for Hematologic Malignancies and some of the recent and exciting advances being seen in the hematology space.
Read More
Trial to Assess PRT2527 Plus Zanubrutinib for Hematologic Malignancies
March 18th 2023The combination of CDK9 plus BTK inhibition has already demonstrated synergistic clinical efficacy vs BTK inhibition alone. Now, a clinical trial collaboration will evaluate PRT2527 and zanubrutinib for patients with hematologic malignancies.
Read More
Using NCCN Guidelines for Chronic GVHD Therapy in Clinical Practice
March 9th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Noah M. Merin, MD, PhD, discussed 3 recommended agents for treatment of chronic graft-vs-host disease. This is the second of 2 articles based on this event.
Read More
Pemmaraju Discusses Data, Approvals, and Challenges for Hematologic Malignancies
March 2nd 2023During a live Twitter Spaces event hosted by Targeted Oncology, Naveen Pemmaraju, MD, explained key abstracts from ASH 2022 and how these data have influenced recent approvals in the hematology field.
Read More